Business
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
FOSTER CITY, Calif., April 29, 2026--Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":280,"url":"https://media.zenfs.com/en/business-wire.com/3592597e5527655b3a1096227da8a752"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Fh4UttK9UytNe1l6viVIkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2MA--/https://media.zenfs.com/en/business-wire.com/3592597e5527655b3a1096227da8a752","width":480,"height":280}},"lazy":false},{"type":"text","content":"FOSTER CITY, Calif., April 29, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report first quarter 2026 financial results on May 6, 2026. Mirum will also host a conference call to discuss the first quarter 2026 financial results and recent corporate progress.","length":340,"tagName":"p"},{"type":"text","content":"Conference call details:Wednesday, May 6, 20264:30 p.m. ET / 1:30 p.m. PT","length":75,"tagName":"p"},{"type":"text","content":"Dial-In:US/Toll-Free: + 1 833 461 5787International: +1 585 542 9983Access Code: 487977865","length":93,"tagName":"p"},{"type":"text","content":"You may also access the call via webcast by visiting the Investors section of Mirum’s corporate website. The archived webcast will be available for replay.","length":155,"tagName":"p"},{"type":"text","content":"About Mirum Pharmaceuticals","length":27,"tagName":"p"},{"type":"text","content":"Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities.","length":350,"tagName":"p"},{"type":"text","content":"The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in ...